What's behind Eli Lilly's latest stock surge?

Traders Union
All News
Stocks
Eli lilly surges 3.67% today

Highlights

Eli Lilly reported a 48% year-over-year revenue surge to $23.0 billion, raising its full-year sales and profit forecast.
Second-quarter charges of $703 million related to Kelonia and Centessa increased the company's effective tax rate to 23.3%.
Eli Lilly stock remains bullish, trading near session highs with an expected five-day range of $1,167 to $1,288 and overbought conditions cautioning for possible consolidation.

Guidance raised despite impairment charges impacting tax rate

Eli Lilly reported second-quarter revenue of $23.0 billion, marking a 48% increase year over year and prompting the company to raise its full-year sales and profit guidance. The results included $703 million in asset impairment and restructuring charges linked to the Kelonia and Centessa deals, leading to the effective tax rate rising from 16.5% to 23.3%. Eli Lilly also received attention in healthcare sector updates and improved its ranking among blue-chip stocks.

Anton Kharitonov, expert at Traders Union, notes that despite the surge in Eli Lilly's share price and raised outlook, underlying risks should not be overlooked. He points out that the spike in asset impairment and restructuring charges has driven the effective tax rate significantly higher. The technical setup looks strong, but overbought signals and neutral oscillators suggest momentum may soon wane. Kharitonov is cautious about the sustainability of the uptrend given potential volatility exceeding 2% and high investor optimism. "Traders should be wary of chasing the rally at these levels, as technical and fundamental cracks may invite a sudden pullback."

Viktoras Karapetjanc, expert at Traders Union, believes Eli Lilly demonstrates robust fundamentals backed by impressive revenue growth and strong sector positioning. He sees the raised guidance as further validation of management's confidence. The bullish structure remains intact as the stock trades well above key moving averages. Karapetjanc expects LLY to test new highs if momentum holds above the $1,230 resistance. "Further growth is likely, and the market offers multiple setups for investors with a forward-looking mindset."

Parshwa Turakhiya, analyst, observes that sentiment around LLY is driven by strong earnings momentum and positive investor reaction. Technical indicators flash mixed signals, with momentum staying bullish but some oscillators turning neutral. He highlights the opportunity for short-term traders as price action flirts with resistance around $1,230. "I see an attractive risk-reward setup here, especially for those ready to capitalize on volatility in the coming sessions."

Uptrend confirmed as multiple indicators flag strong but overbought setup

LLY is trading above its 20-day, 50-day, and 200-day moving averages ($1,170, $1,157, and $1,033), indicating a bullish short-term setup with strong medium- and long-term trend support. The stock remains close to its recent high, with immediate resistance at $1,230 (week high) and support at $1,227 (today high), both levels further validated by the Ichimoku Kijun at $1,179. Technical momentum is firm, as the MACD generates a strong buy forecast, while the ADX signals a neutral trend. The RSI also points to a buy signal, yet the Stochastic RSI and CCI remain neutral. Bull/Bear Power (BBP) signals strong buying dominance, but with an overbought warning present. The intraday tone stays strong, with volatility at 2.46% and upward momentum holding toward the session’s high, though some divergence exists between bullish momentum signals and neutral oscillator readings.

Earlier, analysts noted that Eli Lilly stock demonstrated sustained technical momentum following robust earnings and upward guidance revisions. The current analysis adds further confirmation, identifying a continued bullish setup with the next major catalyst likely to be a decisive move above or below the $1,230–$1,227 price cluster.

Source of Data: LLY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.